Effect of Progestin on the Ovarian Epithelium of Macaques: Cancer Prevention Through Apoptosis?

Abstract

Objective: The apoptosis pathway is a vital mechanism in vivo that functions to eradicate genetically damaged cells prone to malignancy. The purpose of this study was to determine whether oral contraceptives, which confer significant protection against subsequent epithelial ovarian cancer, induce apoptosis in the ovarian epithelium.

Methods: Female cynomologus macaques (N = 75) were randomized to receive a diet for 35 months containing either no hormones, the oral contraceptive Triphasil (Wyeth-Ayerst Laboratories, Philadelphia, PA), the estrogenic component of Triphasil (ethinyl estradiol) alone, or the progestin component of Triphasil (levonorgestrel) alone, each administered in a cyclic fashion. At study termination, the animals underwent ovariectomy and the ovarian epithelium was examined morphologically and immunihistochemically for apoptosis. The percentage of ovarian epithelial cells undergoing apoptosis was measured in each animal and compared between the treatment groups.

Results: The median percentage of ovarian epithelial cells undergoing apoptosis by treatment was control (3.8%), ethinyl estradiol (1.8%), Triphasil (14.5%), and levonorgesrel (24.9%). Compared with control and ethinyl estradiol-treated monkeys, a statistically significant increase in the proportion of apoptotic cells was noted in the ovarian epithelium of monkeys treated with the oral contraceptive Triphasil (P ≤ .01) or levonorgestrel (P < .001), with a maximal effect (six-fold) seen in the group treated with levonorgestrel alone.

Conclusion: Oral contraceptive progestin induces apoptosis in the ovarian epithelium. Given the importance of the apoptosis pathway for cancer prevention, an effective chemopreventive strategy may be possible using progestins or other agents that selectively induced apoptosis in the ovarian epithelium to prevent the development of ovarian cancer.

Keywords

Progetins apoptosis ovarian cancer oral contraceptives

Get full access to this article

View all access options for this article.

References

. Cancer Facts and Figures , 1996. American Cancer Society, Yearly Publication. Atlanta, Georgia: American Cancer Society.

2. Rosenberg L , Palmer JR , Zauber AG , et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994;139:654-661.

3. Stanford JL , Thomas DB , Ray RM , Noonan EA . Epithelial ovarian cancer and combined oral contraceptives: The WHO collaborative study of neoplasia and steroid contraceptives. Int J Epidemiol 1989;18:538-545.

4. Lee NC , Wingo PA , Gwynn ML , et al. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987;316:650-655.

5. Gross TP , Schlesselman JJ . The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 1994;83:419-424.

6. Franceschi S , Parazzini F , Negri E , et al. Pooled analysis of three European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991;49:61-65.

7. Wu ML , Whittemore AS , Paffenbarger RS Jr , et al. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidem 1987;28:1216-1227.

8. Greene MH , Clark JW , Blaynew DW . The epidemiology of ovarian cancer. Semin Oncol 1984;2:209-225.

9. Brenner RM , Slayden OD . Cyclic changes in the primate oviduct and endometrium. In: Knobil E , Neill JD , eds. The physiology of reproduction. Philadelphia: Lippincott-Raven, 1994;541-569.

10.

10. Hotchkiss J , Knobil E . The menstrual cycle and its neuroendocrine control. In: Knobil E , Neill JD , eds. The physiology of reproduction. Philadelphia: Lippincott-Raven, 1999:711-736.

11.

11. Kaiserman-Abramof I , Padykula H . Ultrastructural epithelial zonation of the primate endometrium (rhesus monkey). Am J Anat 1989;184:13-30.

12.

12. Wijsman JH , Jonker RR , Keijzer R , van de Velde CJH , Cornelisse Cj , van Dieriendonck JH . A new method to detect apoptosis in paraffin sections: In situ end-labeling of fragmented DNA. J Histochem Cytochem 1993;41:7-12.

13.

13. Hollander M , Wolfe DA . Nonparametric statistical methods. New York: Wiley, 1973.

14.

14. BMDP statistical software manual. Los Angeles: University of California Press, 1992:549-561.

15.

15. Ferenczy A . Anatomy and histology of the uterine corpus. In: Korman J , ed. Blaustein's pathology of the female genital tract 3rd ed. New York: Springer-Verlag, 1987:257-291.

16.

16. Lockshin RA , Zakeri Z . The biology of cell death and its relationship to aging. In: Cellular aging and cell death. New York: Wiley-Liss, 1996:167-180.

17.

17. Lowe SW , Ruley HE . p53-Dependent apoptosis in tumor progression and in cancer therapy. In: Cellular aging and cell death. New York: Wiley-Liss, 1996:209-234.

18.

18. Canman CE , Chen C-Y , Lee M-H , Kastian MB . DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harbor Symposia on Quantatative Biology, Vol. LIX. Plainnow, NY: Cold Spring Harbor Laboratory Press, 1994:277-286.

19.

19. Chan LN , Zhang S , Cloyd M , et al. N-(4-hydroxyphenyl) retinamide prevents development of T-lymphomas in AKR/J mice. Anticancer Res 1997;17:499-503.

20.

20. Ponzoni M , Bocca P , Chiesa V , et al. Differential effects of N-(4-hydroxyphenyl) retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation. Cancer Res 1995;55:853-861.

21.

21. Delia D , Aiello A , Lombardi L , et al. N-(4-hydroxyphenyl) retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993;53:6036-6041.

22.

22. Seewaldt VL , Kim JH , Caldwell LE , Johnson BS , Swisshelm K , Collins SJ . All-trans-retinoic acid mediates G1 arrest but not apoptosis of normal human mammary epithelial cells. Cell Growth Differ 1995;6:863-869.

23.

23. Lotan R . Retinoids in cancer chemoprevention (review). FASEB J 1996;10:1031-1039.

24.

24. Sankaranarayanan R , Mathew B . Retinoids as cancer-preventive agents (review). JARC Sci 1996;139:47-59.

25.

25. Toma S , Isnardi L , Raffo P , et al. Effects of all-trans-retinoic acid and 13-cis-retinoic acid on breast-cancer cell lines: Growth inhibition and apoptosis induction. Int J Cancer 1997;70:619-627.

26.

26. Oridate N , Lotan D , Mitchell MF , Hong WK , Lotan R . Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: Implications for chemoprevention. J Cell Biochem Suppl 1995;23:80-86.

27.

27. Dolivert V , Ton VanJ , Sarini J , et al. [Current knowledge on the action of retinoids in carcinoma of the head and neck] [Review]. Rev Laryngol Otol Rhinol (Bord) 1996;117:19-26.

28.

28. Kuo SM . Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett 1996;110:41-48.

29.

29. Thompson HJ , Jiang C , Lu J . Sulfone metabolite of sulindac inhibits mammary carcinogensis. Cancer Res 1997;57:267-271.

30.

30. Reddy BS , Wang CX , Samaha H , et al. Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 1997;57:420-425.

31.

31. Gould MN . Cancer chemoprevention and therapy by monoterpenes. Environ Health Perspect 1997;105(Suppl):977-979.

32.

32. Pascale RM , Simile MM , De Miglio MR , et al. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 1995;16:427-430.

33.

33. Thompson HJ , Wilson A , Lu J , et al. Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line. Carcinogenesis 1994;15:183-186.

34.

34. El-Bayoumy K , Upadhyaya P , Chae YH , et al. Chemoprevention of cancer by organoselenium compounds. J Cell Biochem Suppl 1995;22:92-100.

35.

35. Casagrande JT , Pike MC , Ross RK , Louie EW , Roy S , Henderson BE . “Incessant ovulation” and ovarian cancer. Lancet 1979;2(8135):170-173.

36.

36. Whittemore AS , Harris R , Itnyre J , the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. Am J Epidemiol 1992;136:1212-1220.

37.

37. Bast RC Jr , Berchuck A . Ovarian cancer In: Isselbacher KJ , Braunwold E , Wilson JD , Martin JB , Fauci AS , Kaspey DL , eds. Principles of internal medicine. New York: McGraw-Hill, 1994:1853-1858.

38.

38. Rossing MA , Daling JR , Weiss NS , Moore DE , Self SG . OVarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-776.

39.

39. Hild-Petito S , Stouffer RL , Brenner RM . Immunocytochemical localization of estradiol and progesterone receptors in the monokey ovary throughout the menstrual cycle. Endocrinology 1988;123:2896-2905.

40.

40. Press MF , Greene GL . Localization of progesterone receptor with monoclonal antibodies to the human progestin receptor. Endocrinology 1988;122:1165-1175.

41.

41. Liang AP , Levenson AG , Layde PM , et al. Risk of breast, uterine corpus, and ovarian cancer in women receiving medorxyprogesterone injections. JAMA 1983;249:2909-2912.

42.

42. Stanford JL , Thomas DB . Depot-medroxyprogesterone acetate (DMPA) and risk of epithelial ovarian cancer. Int J Cancer 1991;49:191-195.

43.

43. Rodriguez C , Calle EE , Coates RJ , Miracle-McMahill HL , Thun MJ , Health CW Jr . Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:828-835.